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Current update of cerebral embolic protection
devices
Albeir Y. Mousa, MD, John E. Campbell, MD, Ali F. AbuRahma, MD, and
Mark C. Bates, MD, Charleston, WVa
Carotid artery stenting (CAS) has evolved into a viable alternative to carotid endarterectomy. Although CAS outcomes
have improved during the last decade, the associated stroke rate remains higher when compared with carotid endarter-
ectomy. Therefore, the pivotal role of embolic protection devices (EPDs) in minimizing stroke risk cannot be
underestimated as a vital component of CAS. As technology advances, EPDs continue to be refined, and each device
currently on the market has its own advantages and disadvantages. This review provides an overview of the current status
of EPDs and highlights the unique features of each device, followed by suggestions for application in specific clinical
scenarios. ( J Vasc Surg 2012;56:1429-37.)
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uStroke is the third most common cause of death world-
wide. Thirty percent of strokes have been attributed to
atherosclerotic disease of the extracranial carotid artery.
There is level 1 evidence confirming that carotid endarter-
ectomy (CEA) decreases the risk of stroke in symptomatic
and asymptomatic patients.1-3 Carotid artery stenting
(CAS) has evolved as an alternative therapy for carotid
atherosclerotic disease in high-risk patients. The efficacy of
this technique has been validated in multiple studies, in-
cluding randomized controlled studies.4-9
The Carotid Revascularization Endarterectomy vs
Stenting Trial (CREST) investigators9 showed that CEA
and CAS are comparable procedures. This multicenter,
well-designed, prospective, randomized controlled study
examined the primary end points of stroke, myocardial
infarction (MI), and death in 2502 patients. Evaluation was
initiated in the preoperative period and extended to 4 years
after randomization. Although no significant differences
were found between CEA and CAS in the composite end
points, as defined by periprocedural (30 days) death,
stroke, or MI, strokes were more frequent after CAS (4.1%
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ower risk of MI and cranial nerve injury with CAS com-
ared with CEA is counterbalanced by an increased risk of
psilateral stroke events.
Because stroke is themost fearedcomplicationofCAS, there
s a great need for continued efforts to develop the ideal embolic
rotection device (EPD) to minimize embolic events during
ASbefore this treatmentmodality can replaceCEA.The basics
f filter design began with the interpretation of animal studies10
onducted many years ago to evaluate the size of particles that
ay contribute to intracerebral arteriolar occlusion by injection
f microspheres of different sizes into the intracranial arterial
essels. Interestingly, only 2% of 15-m-diameter embolic
pheres were shunted to the cerebral venous circulation, sug-
esting that even microembolic particles can occlude cerebral
rteriolar inflow. The average filter has 100-m pores; there-
ore, microembolization phenomena may occur with the use
f all currently available filters.
Theron et al11 performed the first carotid artery angioplasty
ith an EPD in 1990. The EPD they used was a distal balloon
cclusion (DBO) system that allowedmost of the trappeddebris
o be removed with an aspiration catheter. This was one of the
rst EPD devices to become available, and in their initial report,
he stroke ratewas reducedby50%.DBOsubsequently fell out
f favordue to intolerance anddifficulty inprocedural technique.
evertheless, EPDshave continued to evolve, with various engi-
eering strategies to increase efficacy and deliverability.
The selection of an EPD is mainly guided by a patient’s
natomy and operator preference. Although vascular spe-
ialists have not reached a consensus regarding the ideal
PD, there is a consensus that routine use of an EPD
uring CAS is beneficial and mandatory.12 Indeed, multi-
le studies have demonstrated the feasibility of EPD
se,13-16 with a decrease in the 30-day stroke rate (Fig 1).
raditionally, the most common access is the femoral ap-
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allowed some to use the radial artery as an alternative
approach for CAS.17
CATEGORIES OF EPDs
Three types of cerebral EPDs are currently available
(see Table I for more details).
Fig 1. Bar graph demonstrates the 30-day stroke rate in all
along the time line for these studies. ARCHER II, Acculin
ARCHER III,Acculink for Revascularization of Carotids inH
larizationUsing theBostonScientificEPIFilterWireEX/EZa
with ev3 Arterial Technology Evolution; CREST, Carotid Re
Protection with Flow Reversal; EPIC, FiberNet Embolic P
Evaluation of the Medtronic AVE Self-Expanding Carotid S
Stenosis; SAPPHIRE, Stenting and Angioplasty with Protect
Registry Study to Evaluate the Neuroshield Bare Wire Cereb
Carotid Endarterectomy.
Table I. Technical details of selected embolic protection d
Type of EPD Device name M
Distal filter RX Accunet (Fig 4) Abbott
Angioguard RX (Fig 6) Cordis
Emboshield Nav6 (Fig 5) Abbott
FiberNet (Fig 7) Medtro
FilterWire EZ (Fig 3) Boston
SpiderFX (Fig 2) Covidi
Distal occlusion GuardWire Medtro
Proximal occlusion Gore NPS W. L. G
Mo.Ma Ultra Medtro1. Flow preservation devices: distal filters (DFs) t. Distal occlusion devices (DODs): DBOs
. Proximal protection devices:
a. Mo.Ma Ultra Proximal Protection System (Medtronic
Invatec, Frauenfeld, Switzerland)
b. Gore Flow Reversal System (W. L. Gore and Asso-
ciates, Flagstaff, Ariz)
ach category is associated with advantages and disadvan-
nt studies of carotid artery stenting; the stroke rate decreases
Revascularization of Carotids in High-Risk Patients trial II;
Risk Patients trial III;CABERNET,Carotid Artery Revascu-
EndoTexNexStent;CREATEII,CarotidRevascularization
larization Endarterectomy vs Stent Trial; EMPIRE, Embolic
tion System in Carotid Artery Stenting Trial; MAVErIC,
System with Distal Protection in the Treatment of Carotid
Patients at High Risk for Endarterectomy; SECURITY, A
otection System and Xact Stent in Patients at High Risk for
es (EPDs)
cturer
Pore size Vessel size Crossing profile
(m) (mm) (F)
ular 150 3.25-5.0 3.5-3.7
100 4.5-7.5 3.2-3.9
ular 140 2.5-7.0 2.8-3.2
nc 40 3.5-7.0 1.7-2.9
ntific Corp 110 3.5-5.5 3.2
50-300 3.0-7.0 3.2
nc . . . 3.0-5.5 2.8
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Volume 56, Number 5 Mousa et al 1431Flow preservation devices (DFs). This type of pro-
tection is the most commonly used neuroprotection today.
The DF allows antegrade cerebral flow during the entire
procedure, with a lower risk of intolerance compared with
proximal protection devices and DOD systems, while al-
lowing intraprocedural angiograms and minimal deviation
from standard balloon angioplasty techniques. Filter de-
signs vary: some can be advanced over a 0.014-inch wire,
and others are attached to a steerable wire tip. Crossing
profiles range from the 1.7 F FiberNet (Lumen Biomedical
Inc, Plymouth, Minn) to the 3.9 F Angioguard RX (Cordis
Corp, Bridgewater, NJ).
The main limitations of DFs are related to the need to
cross the lesion with the wire and filter before initiating
protection. In addition, the escape of particles with filter
bias and malapposition, along with microembolic risk in-
herent to the pore size of 100 to 150 m needed to
maintain flow, are significant considerations during use of a
DF. Data from multiple studies showed that 60% of the
typical embolic load can be 60 m, with resultant em-
bolic load to the distal vascular system of up to 60,000
particles. The average arteriolar diameter is 12 to 16 m;
therefore, there is a significant theoretic risk of microem-
bolic intracerebral arteriolar occlusion, even with the cur-
Table II. Recommended application and advantages/disa
Type of EPD Recommended applications
Distal filter Standard lesion Pres
Cannot tolerate occlusion Inte
Stenosis not preocclusive Rea
Con
in
Distal occlusion Preocclusive lesion Low
ICA or CCA tortuosity Hig
Uni
Proximal occlusion Fresh thrombus at bifurcation Avo
Crescendo TIAs Pro
Severe distal ICA tortuousities Tre
Intracranial stenosis Use
Rev
CCA, Common carotid artery; ICA, internal carotid artery; TIA, transient
Fig 2. Diagram of a Spider FX (Covidien, Mansfield, Mass) em-
bolic protection device (EPD).rent DFs.10,18 Although there is the inherent disadvantage Mf particles 60 m escaping to the target organ, most
xperts still believe that DFs are more efficacious devices
han DODs, given the risk of particles 60 m escaping
hen the balloon is deflated if adequate aspiration cannot
e performed secondary to the watershed area present at
he margin of the balloon.18-20
Moody et al21,22 described a decrease in cognitive
unction in patients after coronary artery bypass grafting
nd found in postmortem studies that microemboli were
ypically 70 m. Interestingly, the patients in Moody’s
eries had clinically silent events, with no evidence of stroke
ostoperatively, only to have the embolic event discovered
ubsequently when the indolent symptoms of cognitive
unction issues surfaced during follow-up. Accordingly, we
elieve special attention must be exercised when consider-
ng CAS patients with poor cognitive function or reserve.
Currently, six DF devices are predominately in use:
piderFX (Covidien, Mansfield, Mass; Fig 2), FilterWire
Z (Boston Scientific Corp, Natick, Mass; Fig 3), RX
ccunet (Abbott Vascular, Santa Clara, Calif; Fig 4), Em-
oshield Nav6 (Abbott Vascular; Fig 5), Angioguard RX
Cordis Corp, Bridgewater, NJ; Fig 6), and FiberNet EPD
Lumen Biomedical, Inc; Fig 7). Table II summarizes the
ain characteristics of each DF.
The DODs. The GuardWire Temporary Occlusion
nd Aspiration System (Medtronic Corp, Minneapolis,
tages of various embolic protection devices (EPDs)
Advantages Disadvantages
antegrade flow Higher crossing profile
rteriography Too stiff for tortuous vessel
debris capture May clog with debridement
imaging possible throughout
ntion
Difficult to steer
Filter entrapment in stent
May not capture all debris
Delivery/retrieval catheters
may embolize
le Flow cessation
ibility Risk of ICA dissection
l size No angiogram during stent
bolization during procedure Large sheath
before crossing Risk of CCA injury
eocclusive lesions Cerebral blood flow reversed
ewire of choice
of flow in ICA
Stagnant flow and difficulty
with imaging during
intervention
ic attack.
ig 3. Diagram of a FilterWire EZ (Boston Scientific Corp,
atick, Mass) embolic protection device (EPD).dvan
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l-time
trast
terve
profi
h flex
versa
id em
tects
ats pr
s guid
ersalinn) is a DOD that has a 3- to 6-mm diameter and uses a
W
e
p
o
t
g
a
(
l
c
e
t
o
d
m
o
M
a
p
fl
b
F
c
fl
i
n
b
t
i
d
C
m
e
b
b
M
(
s
n
t
p
e
r
r
p
s
b
r
h
p
d
c
w
JOURNAL OF VASCULAR SURGERY
November 20121432 Mousa et al0.014-inch system with a compliant balloon. DODs are
characterized as having a low profile, requiring a very short
landing zone, and having the ability to be deployed in
tortuous vessels. They also have the ability to allow the
aspiration of embolic particles 100 m.
Inflation of the compliant balloon is achieved through
a 0.014-inch wire inflation system. The proximal portion of
the wire is designed with an inflation device that allows
balloon inflation when the window is opened. Once the
balloon is inflated and complete occlusion is confirmed on
the angiogram, the wire can be used as a rail for the rest of
the procedure. Careful observation is required after balloon
deployment to rule out any leaks. After CAS is completed,
an export aspiration catheter is advanced into the cul-de-sac
to evacuate any debris, followed by deflation of the balloon.
The main concern with the DOD is intolerance, sec-
ondary to circulation arrest in the internal carotid artery;
Fig 4. Diagram of an RX Accunet (Abbott Vascular, Santa Clara,
Calif) embolic protection device (EPD).
Fig 5. Diagram of an Emboshield Nav6 (Abbott Vascular, Santa
Clara, Calif) embolic protection device (EPD).
Fig 6. Diagram of an Angioguard RX (Cordis Corp, Bridgewa-
ter, NJ) embolic protection device (EPD).
Fig 7. Diagram of a FiberNet (Lumen Biomedical Inc, Plym-
outh, Minn) embolic protection device (EPD).therefore, careful preoperative evaluation of the circle of millis and the status of the contralateral carotid artery is
ssential. In addition, the occlusion balloon is inflated to a
oint of occlusion, which causes the obvious disadvantage
f the inability to adequately visualize the lesion secondary
o cessation of antegrade flow in the target vessel. Angio-
rams can be performed, but embolic material can reflux
nd escape the target vessel into the external carotid artery
ECA) or, in extreme cases, into the thoracic aorta. This can
ead to stroke if the ECA collaterals connect to the cerebral
irculation or if embolic material refluxes into the contralat-
ral carotid artery.
Another potential issue is the inability to remove all of
he embolic material from the watershed area on either side
f the balloon. Finally, there is potential for spasm or even
issection of the artery at the site of deployment if there is
ovement of the DOD system or if the balloon is
verinflated.
Proximal protection devices. These include the
o.Ma Ultra and the Gore Flow Reversal System. These
re the newest advancements in EPDs, allowing embolic
rotection before the lesion is crossed using flow stasis and
ow reversal. The Mo.Ma uses common carotid and ECA
alloons in a single-delivery catheter, whereas the Gore
low Reversal System creates a flow circuit between the
arotid artery and femoral vein to initiate gradient-driven
ow reversal. Themain advantage of these devices is that no
nteraction with the plaque occurs until the reversal/stag-
ation of flow is initiated.
Some reports have indicated that 15% of cerebral em-
oli occur during the initial crossing of the lesion,18 and
hese devices also provide protection during the most crit-
cal time of the highest burden of cerebral emboli, which is
uring poststenting balloon angioplasty.23 Using the
oulter Counter technique (Beckman Multisizer 3; Beck-
an Coulter Inc, Fullerton, Calif) for particle analysis in an
x vivo model, Coggia et al10 recorded40,000 microem-
oli during guidewire passage and thousands of microem-
oli during stent placement.
A recent prospective single-center trial, the Silk Road
edical Embolic PROtectiOn System: First-In-Man
PROOF) study, evaluated the MICHI neuroprotection
ystem (Silk Road Medical Inc, Sunnyvale, Calif).24 This
ovel technique uses controlled reverse flow through an 8 F
ranscervical approach. The anticipated advantages are to
rovide short and direct access for balloon and stent deliv-
ry, in addition to all of the perceived benefits of flow
eversal, to minimize microemboli and macroemboli from
eaching the cerebral circulation. This study included 44
atients with a primary composite end point of major
troke, MI, or death 30 days perioperatively. Embolic
rain injury was accessed with diffusion-weighted magnetic
esonance imaging (DW-MRI), which was performed 24
ours before the procedure. Within the first 48 hours, 31
atients underwent DW-MRI, and 16% of those had evi-
ence of a new ischemic brain injury; however, all remained
linically asymptomatic. Transient flow-reversal intolerance
as encountered in 9% of patients, who were treated by
inimizing the duration of flow reversal. This study points
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Volume 56, Number 5 Mousa et al 1433out the feasibility and safety of transcervical CAS using the
MICHI neuroprotection system. In addition, DW-MRI
demonstrates that controlled reverse flow may provide an
equivalent embolic protection to CEA.
In another recent retrospective analysis, Alvarez et al25
evaluated early- and medium-term outcomes of transcervi-
cal CAS with flow reversal in 219 patients aged 70 years
who were at high risk for CEA. The main objective of their
study in using the transcervical approach was to avoid arch
manipulation and its associated risks, such as atheroembo-
lism, and the higher incidence of difficult anatomy in the
elderly population. For the entire group, 30-day combined
stroke/death/MI rate was 2.2% (stroke, 1.8%; MI, 0.45%);
however, in symptomatic patients (44%), the combined
stroke/death/MI rate was 5.1% (stroke, 4.1%). In the
meantime, none of the asymptomatic patients suffered
stroke, MI, or death postoperatively. Technical failure was
3.7%, mainly secondary to an inability to cross the lesion.
The incidence of 70% restenosis was 3% at 1 year and 8%
at 2 and 3 years. Only one patient experienced an ipsilateral
stroke during follow-up. The overall survival rate was 94%
at 1 year and 90% at 2 and 3 years. The authors concluded
that the transcervical approach with flow reversal is a safe
technique for treating carotid stenosis in patients aged70
years old, and avoiding all aortic arch manipulations, espe-
cially in those patients with tortuous supra-aortic vessels,
augments the favorable results in this study.25
From these observations, proximal protection has been
recommended for the following indications26-28:
1. Symptomatic carotid ulcerative plaque/filling defect in
patients who are not candidates for open surgery
2. Symptomaticpatientswith abnormal transcranial echoeswith
reduced cognitive function
These indications may be broadened to include all symp-
tomatic patients if randomized trials confirm that microem-
boli using DFs has an effect on cognitive function.
LITERATURE REVIEW
An interesting ex vivo model26 examined the differ-
ences between DF and proximal occlusion with flow rever-
sal (POFR). This model used intact carotid plaques re-
moved from patients en bloc. When DF devices were used
in 6-mm-diameter polytetrafluorethylene tubes, the per-
centage of trapped emboli was poor (up to 27.8%). There
was no difference between the devices regarding capture of
embolic material; however, capture capability function of
these filters improved with oversizing the filter, from 22%
(same size) to 51.4% (oversize; P .001). However, POFR
efficiency improved with increasing back pressure and with
repeated aspirations. When the efficiency of POFR was
assessed with forward flushing volumes, similar to those
used for DF, the efficiencies were similar.
Another model27 was used to evaluate capture effi-
ciency, pressure gradient, flow rate, and vascular resistance
of four EPDs; namely, the SpiderFX, FilterWire EZ, RX
Accunet, and Emboshield. Themodel used a silicone phan-
tom with 70% stenosis at the proximal internal carotid mrtery, in which a blood-mimicking solution (glycerol/
eionized water) was circulated at a mean peak velocity for
he common carotid artery. The SpiderFX trapped themost
articles and was associated with the slightest increase in
ressure gradient for both masses of microspheres injected.
he SpiderFX and FilterWire EZ were associated with the
lightest decreases in flow rate and the slightest increases in
ascular resistance. The SpideRX had the greatest device-
pecific porosity, at 50.4%, and the Emboshield had the
owest, at 2.2%. This study concluded that the SpiderFX
nd the FilterWire EZ had the best overall performances;
owever, these data do not apply to the new version of the
mboshield, the Emboshield Nav6, that was released after
his study and is currently available. This study demon-
trated that design features, such as porosity and pore
ensity, are important parameters for improving the effec-
iveness of EPDs.
A large retrospective multicenter study28 evaluated
160 CAS procedures, using nine types of EPDs. The risk
f adverse procedural events was 0.9% in protected and
.3% in unprotected procedures (P .12). Compared with
he most frequently used device (FilterWire), there was no
ignificant difference in the risk of procedural adverse
vents for any of the other EPDs. A pairwise comparison of
roximal occlusion balloons vs filters, distal occlusion bal-
oons vs filters, and proximal vs distal occlusion balloons
evealed no significant difference in the risk of procedural
r 30-day adverse events. There was no significant differ-
nce in the risk of procedural events between eccentric and
oncentric filters; however, the relative risk of eccentric
ompared with concentric filters at 30 days was 0.59 (un-
djusted 95% confidence interval [CI], 0.38-0.92; P 
04). This difference was still apparent after adjustment for
isk factors (relative risk, 0.61; 95% CI, 0.39-0.95, P .06)
ut not after adjustment for risk factors and open-cell vs
losed-cell stent type (relative risk, 0.76; 95% CI, 0.47-
.22; P  .51). The authors concluded that the use of
PDs is associated with a lower risk of adverse procedural
vents and that there was no significant difference in risks of
dverse procedural events between different devices and
ypes of devices.
The investigators of the Carotid Acculink/Accunet
ost-Approval Trial to Uncover Unanticipated or Rare
vents (CAPTURE)29 indicated that CAS is safe with the
se of EPDs. In a prospective multicenter registry, 353
hysicians at 144 sites enrolled 3500 patients. The 30-day
rimary end point event rate was 6.3% (95% CI, 5.5%-
.1%), and the difference between the experience levels of
he three operators (5.3%, 6.0%, and 7.4%) from most to
east experienced was not significant (P .31). A trend was
oted, however, and a statistical differencemight have been
resent with a larger patient population. Outcomes did not
iffer among physician specialties when adjusted for case-
ix, and no unanticipated device-related adverse events
ccurred.
Efficacy of EPDs. The efficacy of EPD protection is
ot just limited to macroembolization but also extends to
icroembolization, which can be of great concern as well.
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November 20121434 Mousa et alAs we learned from the coronary literature, the National
Institutes of Health coma scale cannot precisely evaluate
microembolization, yet these tiny particles can affect cog-
nitive function to some extent. One study that evaluated
the efficacy of EPDs found subclinical microembolization
occurred with particles ranging from 10 to 70m.21 Trans-
cranial Doppler (TCD) monitoring during CEA has dem-
onstrated that particles sized10 m do not contribute to
a large clinical stroke but are associated with cognitive
deterioration.30
The two main diagnostic tools to examine cerebral
emboli during CAS are TCD and DW-MRI.31,32 A recent
study33 examined the periprocedural embolic events re-
lated to CAS detected by DW-MRI, which was used to
assess 44 patients (mean age, 68 years) who underwent
protected CAS and had DW-MRI before and after inter-
vention. A proximal EPD was deployed in 25 patients
(56.8%) and a DF in 19. A symptomatic target lesion was
found in 15 patients (60.0%) who had proximal protection,
and 10 (52.6%) were symptomatic in the distal protection
group. Significant abnormalities were detected when DW-
MRI was performed after CAS with DF, which augmented
the concern of silent cerebral injury from the microem-
boli.34 Although most of the embolic events were clinically
silent, new lesions were seen on the postinterventional
DW-MRI in seven of 25 patients (28.0%) in the proximal
EPD group vs six of 19 (32.6%) with a DF, which was not
significant. No significant differences were noted in the T2
appearance of the new lesions or in the number of new
lesions observed away from the vascular territory of the
stented artery.
Perceived difference between filter and DODs. Zahn
et al35 evaluated 1734 patients in a prospective CAS regis-
try. Of these patients, 729 were treated with an EPD,
including 553 (75.9%) with a DF and 176 (24.1%) with a
DOD. Patients treated with DODs were more likely to be
treated for symptomatic stenosis (64.5% vs 53.4%, P 
.011). The carotid lesions in patients treated with a DOD
seemed to be more complicated, as expressed by a higher
proportion of ulcers (P  .035), severe calcification (P 
.039), a longer lesion length (P  .025), and a higher
preinterventional grade of stenosis (P .001). The median
duration of the CAS intervention was 30 minutes in the
DOD group, compared with 48 minutes in the DF group
(P  .001). No differences in clinical event rates were
observed between the two groups of EPD patients. A
multivariate analysis on the occurrence of the combined
end point of in-hospital death or stroke found no difference
between DF and DOD. This study concluded that al-
though DF is currently the preferred method of EPD in
clinical practice, DF-EPD and DOD seem to be equally
effective during CAS.
PITFALLS OF EPDs
Pitfalls of DFs
Selective protection. We use this term to remind the
reader that embolic particles sized 100 m will escape phrough the filter’s pores. This may be an issue in patients
ith decreased cognitive function or poor reserve.
Filter occlusion or flow stagnation. This occurs sec-
ndary to thrombosis of the filter or when a large embolic
oad overwhelms the capacity of the filter. Special attention
o preprocedural antiplatelet and anticoagulation status
efore navigation through the carotid lesion is an impor-
ant preventive measure. Regardless of the cause, any slow-
ng of flow or flow stagnation should prompt the operator
o urgently perform aspiration, which can be done with any
umber of aspiration catheters. Failure to perform angiog-
aphy before filter removal could result in missed filter
cclusion, and embolic stroke can occur during filter
etrieval.
Casserly et al36 observed cases where there was angio-
raphic evidence of a significant reduction in antegrade
ow in the internal carotid artery proximal to the filter
evice, which is referred to as “slow-flow” phenomena. In
14 patients who underwent 453 carotid artery interven-
ions using DF, slow flow occurred in 10% and most
ommonly occurred after poststent balloon dilatation
71.4%). A multivariate logistic regression analysis identi-
ed predictors of slow flow as recent history (6 months)
f stroke or transient ischemic attack, increased stent diam-
ter, and increased patient age. The 30-day incidence of
troke or death was 9.5% among patients with slow flow
ompared with 2.9% in patients with normal flow (2 
.73; P .03). This study demonstrated that slow flow is a
redictor of worse patient outcomes and that late compli-
ation risks may be related to plaque prolapse between the
tent struts in this complex patient subset having a high
urden (large vessel) of soft plaque (recent symptoms).
Filter entanglement. Filter entanglement can occur
hen the filter is inadvertently withdrawn and becomes
ntangled in the distal portion of the stent or when the filter
ire is trapped over the edge of the stent. This dreaded
omplicationmight require open surgical extrication. Care-
ul management of the wire and fluoroscopy can avoid this
uring advancement of all catheters because the sheath can
rolapse into the aorta. The tip of the sheath/guide should
e visualized during all steps of the procedure and never out
f the field of view. Also, the use of a “floating filter” can
ive the operator some leeway for wire movement when
ompared with a filter attached to the wire.
Another issue in this category reported by our group is
he “marriage” between the filter system and the balloon
atheter, which is due to inadvertent aggressive interaction
etween the balloon catheter and the filter during post-
tenting balloon angioplasty. This also can have a disastrous
utcome because the filter cannot be retrieved with the
raditional method. Our group has reported a technique for
ndovascular retrieval if this occurs, but obviously, the best
revention is to closely watch the catheters during ex-
hange and avoid the complication from occurring.37
Filter tear. To compress the filter into a low-profile
elivery system, the polymer membrane is very thin. In
atients with complex, large calcified captured material, the
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material or difficulty with extrication.
Pitfalls of DBOs
Intolerance. Ischemia occurs in 20% of patients with
occlusion of the ipsilateral carotid artery, and understand-
ing collateral cerebral blood flow is critical; thus, preoper-
ative knowledge concerning the circle of Willis and ex-
tracranial collateral vessel patency is imperative. Patients
with an intact circle of Willis and patent inflow vessels
generally remain asymptomatic throughout the interven-
tion. Patients with subclavian steal syndrome, intracranial
disease, or an incomplete circle of Willis often have symp-
toms, which can range from a gradual decrease in commu-
nication to hemiparesis and seizure. In our experience,
minimizing the occlusion time to8minutes decreases the
risk of cerebral ischemia.
Watershed embolic zones around the proximal por-
tion of the occlusion balloon. As described by Zahn et
al,35,38 the distal balloon in smaller vessels will likely have
larger angles with more chance for retained particles at
these angles. They recommended advancing the export
catheter for aspiration during balloon deflation. In larger
vessels, angles around the balloon are less prominent with
less chance of retained particles (Fig 8).
Particle reflux. This will occur when blood in the
cul-de-sac is replaced with contrast during “test injections.”
These particles will reflux into the ECA with a chance of
collateral embolization or paradoxic stroke. Avoiding injec-
tions after angioplasty can reduce this complication.
Premature deflation. Special attention should be
considered to prevent inadvertent pulling on the proximal
end of the wire when the balloon is inflated, because this
can contribute to accidental separation of the occluding
inner core mechanism and premature balloon deflation.
Vessel mismatch. When the target vessel diameter is
larger than the balloon, the balloon can be overinflated by
disconnecting the wire from the inflation device with the
port closed and reloading the system with additional vol-
ume. However, this is outside the instructions for use for
that device and should be avoided, if possible.
Vessel injury. This can occur if the balloon is over-
sized for the target vessel or if the balloon is inadvertently
withdrawn during the procedure.
Pitfalls of proximal protection
Intolerance. The biodynamics of this is similar to the
distal occlusion balloon; however, in the reversal system,
there is more opportunity to evacuate the debris-filled
cul-de-sac at any time. Understanding the flow circuit is
crucial to the procedure. If the patient starts to have cere-
bral symptoms, discontinuation of reversal or resumption
of antegrade flow is imperative. Unlike with DBO, ante-
grade flow can be quickly established in the flow reversal
model because the cul-de-sac is always maintained clear of
debris. In the case of static proximal occlusion, maneuvers
must be done when symptoms start, including completion
of the step in process and export of embolic material. dHigher risk of access complication. This complica-
ion is present with both proximal protection systems sec-
ndary to the large sheath size required. Also, with the flow
eversal system, arterial and venous access are both re-
uired, which can lead to venous access complications as
ell.
Carotid vacuum effect. This can occur during active
ow reversal, which can result in elongation and constric-
ion of the deployed stent.
Anatomic variants. The normal anatomic variant of a
eparate origin of the superior thyroid artery from the ECA
an contribute to incomplete flow control/reversal.
itfalls for all EPDs
Vasospasm. This can contribute to periprocedural
troke, especially in patients with an incomplete circle of
illis or contralateral carotid artery occlusion39-41 and is
ore likely to be encountered during distal occlusion or
lter placement. Vasospasm is secondary to vessel trauma,
nd caution has to be exercised when deploying a filter or
istal balloon. Theoretically, floating filters may be less
raumatic to the carotid artery than fixed filters and cause
ess vessel spasm. Also, slow distal balloon inflation or
ig 8. Diagram demonstrates the watershed area when a distal
alloon occlusion device is used for embolic protection.eflation is recommended with DBO devices. Intra-arterial
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November 20121436 Mousa et alpapaverine or nitroglycerine injection may be needed to
relieve spasm, and rarely, low-pressure balloon inflation is
needed to release the spasm if the patient is having ischemic
symptoms.
Arterial dissection. Again, this is more common with
DBO and DF placement. Flow-limiting dissection can be
treated with self-expanding stents. If not flow-limiting,
anticoagulation and imaging follow-up is recommended.
Prolonged intervention time. The use of EPDs has
extended the intervention time by an average of 10 min-
utes. Carotid angioplasty takes a median of 45minutes with
the use of an EPD vs 35 minutes without (P  .001).38
Equipment failure. Equipment failure can include
but is not limited to partial or complete DF fracture/
embolization, unwanted occlusive balloon deflation, or the
inability to deflate the occlusion balloon.
Trapped guidewire. Trapped guidewire occurs in
0.2%.8
Fasciculations. Muscle twitching occurs in 15% with
OPD.8
Difficult retrieval. This occurs especially with an in-
crease in the tortuosity index 80° and with calcified
plaque.42
CONCLUSIONS
Improvements in technology and a better understand-
ing of the pathology of carotid plaque have contributed to
a significant decrease in the stroke risk associated with CAS.
Embolization occurs during all transcatheter interaction
with atherosclerotic plaque, and the brain is unforgiving.
The intuitive benefit of EPDs amplifies the ethical concerns
about a randomized trial because withholding embolic
protection in the control arm seems unethical. Accordingly,
few controlled randomized data are available to confirm the
reduced stroke risk with EPDs, but the compelling preclin-
ical data and improvement in outcomes through time sup-
port the current expert consensus that EPDs are mandatory
in the domain of CAS.
There is no panacea for protection: filters may have mi-
croemboli, volume threshold, and entanglement; distal occlu-
sion has intolerance and paradoxic embolization; and proxi-
mal flow occlusion has intolerance and a higher access profile.
The ideal device has yet to be defined; however, understand-
ing the feasibility and limitations of these devices is crucial for
better usage by vascular specialists.
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